MAY 28, 2014 10:30 AM PDT

Heavy/Light Chain Combination Assays: What Laboratories should know about M-Protein detection

C.E. CREDITS: CE
Speakers
  • Senior Director of Scientific Affairs, Binding Site
    Biography
            Richard M. O'Hara, Jr. grew up in Texas.  He received a baccalaureate degree in Biology from the University of Texas at Austin.  After working as a research associate for a few years he entered the Immunology Graduate Program at The University of Texas Southwestern Medical School in Dallas, Texas.  Dr. O'Hara spent the final two years of his graduate training at Dalhousie University in Halifax Nova Scotia working with the group that established the first Liver Transplant program in the region.      Following his graduate training he and his family moved to Boston where he entered a postdoctoral training program at Harvard Medical School, working on mechanisms of T cell mediated immune regulation.  He entered the pharmaceutical industry, joining Genetics Institute (later Wyeth Research) as a research scientist in 1988.  His work on cytokine biology led to the development of two new therapeutic drugs and several US patents in hematology and oncology.  Later work in the role of costimulation in graft rejection and autoimmunity led to the development of several other drug candidates.      In 2007, after more than twenty years of research in the fields of autoimmunity and transplantation, he joined The Binding Site as Sr. Director of Scientific Affairs.  In his role at Binding Site, Dr. O'Hara has presented extensively at major US academic medical centers on the characterization on monoclonal proteins in patients with Multiple Myeloma and other Plasma Cell Dyscrasias.    

    Abstract:

    Traditional testing methods for monoclonal protein in Plasma Cell Dyscrasias correctly identify a majority of patients. However, limitations in these methods can cause patients to be missed at diagnosis. Furthermore, difficulties in traditional methods of measuring monoclonal proteins have restricted the ability to measure M-proteins at low levels thereby limiting the laboratory and the clinician, particularly in identifying patients who have minimal residual disease.

    In the past decade, assays which can measure immunoglobulin free light chains has improved detection of patients with Multiple Myeloma and related diseases, as well as providing a more sensitive tool for measuring a patients response to therapy. However, that assay is limited in that not all patients with monoclonal gammopathy show abnormal free light chain measurements. Within the last year, a novel assay which can identify and quantitate individual immunoglobulin heavy chain/light chain pairs has received FDA approval. Like Immunofixation, this assay has the ability to identify m-protein heavy chain and light chain isotypes. However, unlike Immunofixation, the heavy chain/light chain combination assay is quantitative and provides information which is independent of complicating factors such as changes in hematocrit. This heavy chain/light chain combination assay shares with the free light chain assay the ability to measure the analyte in normal individuals, providing exquisite sensitivity when measuring patients in relapse or with minimal residual disease.

    The heavy chain/light chain combination assay is not intended to replace the free light chain assay but rather provides complementary information which enhances the laboratorys ability to provide quantitative information on M-protein production. Utilizing both assays,will enhance the ability of the laboratory and the clinician to evaluate patient tumor load at diagnosis and in response to therapy.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...